A Case-Control Study for Multidrug-Resistant Tuberculosis: Risk Factors in Four European Countries

Abstract

The aim of this study was to detect risk factors for multidrug resistance in patients with pulmonary tuberculosis in four European Union countries: France, Germany, Italy, and Spain. A prospective epidemiological case control study was conducted, made up of patients with clinically diagnosed and microbiologically confirmed pulmonary tuberculosis in the four countries between 1997 and 2000. A total of 138 cases and 276 controls were studied. Considering the four countries as a whole, the most statistically significant risk factors were as follows: intravenous drug use (OR 4.68); asylum-seeker support (OR 2.55) as income factor; living in a nursing home (OR 2.05); previous tuberculosis (OR 2.03) with pulmonary location; prison (OR 2.02); known tuberculosis contacts (OR 2.01); immunosuppression other than human immunodeficiency virus (HIV) (OR 1.96); acquired immunodeficiency syndrome (AIDS) (OR 1.96); current tuberculosis with pulmonary location (OR 1.77); and health-care worker (OR 1.69). These risk factors will have to be taken into account in the European Union as a whole, as well as in each individual country, to establish a health policy of monitoring and control for these cases of multidrug resistance. Although rare, their seriousness makes them particularly important.

Risk factors of multi-drug resistant tuberculosis in urban Allahabad, India

“…Similar finding was observed by Casal et al who reported positive history of contact with tuberculosis in 22.5% MDR-TB patients. 19 In MDR-TB patients, most 51 (94.44%) had either no or unknown history of contact with MDR-TB patient. Only 3 (5.55%) patients of MDR-TB gave positive contact history.…”

“…[9][10][11] It is also associated with higher case fatality rates (50 -80%) as a result of drug toxicity. 9,10 It is known that epidemiologic information on risk factors of MDR-TB is important for prevention and control of the spread of the disease in countries where drug resistance is a major threat. 12 The disease is not only a medical problem or a public health problem but is also a critical social problem of great magnitude.…”

Risk factors of Multidrug Resistant Tuberculosis in central Nepal: A pilot study

“…18 A prospective epidemiological case control study conducted in Europe found that previous tuberculosis treatment was found to be the most significant risk factor for MDR-TB. 19 Previous treatment for tuberculosis has been consistently associated with…”

Natural products as lead compounds in drug discovery

“…The related compound, Sulopenem 94, is in Phase I trials [193]. Faropenem daloxate 95 is a penem-type β-lactam in the treatment of bacterial sinusitis (BS), chronic bronchitis (CB), CAP and uncomplicated SSSIs [194]. …”